Key result
Concurrent administration of doxorubicin and dexrazoxane was well tolerated with minimal side-effects in 25 tumour-bearing dogs.
Why the study?
Is concurrent administration of dexrazoxane and doxorubicin safe and well-tolerated in tumour-bearing dogs?
Observational (n=25)
Is concurrent administration of dexrazoxane and doxorubicin safe and well-tolerated in tumour-bearing dogs?
Concurrent administration of dexrazoxane and doxorubicin appears safe and well-tolerated in tumour-bearing dogs, supporting further studies on its cardioprotective efficacy.
No takes yet. Share an insight, caveat, or question.
Supports tolerability in canine oncology; hypothesis-generating for cardioprotection with controlled trials needed.
FitzPatrick et al. (2010) conducted an observational in Cancer (n=25). Concurrent doxorubicin and dexrazoxane was evaluated on Haematologic, gastrointestinal and cardiovascular toxicities. Concurrent administration of doxorubicin and dexrazoxane was well tolerated with minimal side-effects in 25 tumour-bearing dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: